EANS-News: november Aktiengesellschaft / Announce Asset Deal with MICROBIONIX - affiliated companies PROGEN/Multimetrix take over personnel and laboratory equipment from MICROBIONIX

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Mergers - Acquisitions - Takeovers

Cologne, Heidelberg, Regensburg (euro adhoc) - Effective January 1,
2011 PROGEN Biotechnik GmbH, Heidelberg, and Multimetrix GmbH,
Regensburg, both affiliated companyies of the november AG, are taking
over personnel and laboratory equipment of MICROBIONIX GmbH as part
of an asset deal. Thus, PROGEN/Multimetrix are broadening their
product range in the area of the Luminex® technology by services
hitherto offered by MICROBIONIX, including testing services, bead
coupling and sample testing on customer demand and make available
existing knowhow to implement this extended offering.
(www.multimetrix.com/en/service/testservice.html) The association of
PROGEN and Multimetrix will strengthen the competence in the
multiplex technology, and the segment of customized test services
with an extended panel of parameters for sample testing is
significantly expanded. With the Luminex® technology, even in small
sample volumes several analytes can be detected fast and
simultaneously. Flexible parameter panels can be used for complex
analysis of multiple preclinical, clinical and research issues or
epidemiological studies in fields like e.g. infectious diseases. The
november AG expects that this takeover generates a considerable
increase in competence which will have a further significant positive
impact on sales in the segment of multiplex technology based on the
Luminex® platform.

About Luminex® Technology The xMAP® (Multi Analyte Profiling)
technology developed by Luminex® (www.luminexcorp.com) is an
innovative assay platform for a large range of applications. With
this technology it is possible to simultaneously test 100 parameters
in one test run. Thus, the user saves time and sample material. The
technology is based on microscopically small polystyrene beads which
are coated with antigens e.g. against different infectious diseases.
The automated process allows the beads to identify up to 100
different analytes from one sample. This very sensitive and specific
detection enables fast screening tests of many different samples as
well as a differential sample analysis.

About november AG / PROGEN Biotechnik GmbH / Multimetrix GmbH
november AG, Cologne is an investment and holding company, listed in
the prime standard of the regulated market of the German stock
exchange (Deutsche Börse), with special focus on medical technology,
biotechnology, and environmental technologies and 100% shareholder of
PROGEN Biotechnik GmbH (www.progen.de). PROGEN Biotechnik GmbH,
Heidelberg, is manufacturer of in vitro diagnostics (borrelia, hanta
virus, FSME) and research reagents (antibodies, polypeptides, AAV,
hyperphage, www.yperphage.com), certified to DIN EN ISO 13485:2007,
as well as for the production of multiplex assays for the Luminex®
platform. PROGEN is member of the VDGH (German Association of
Diagnostic Manufacturers) and major shareholder of Multimetrix GmbH,
Regensburg.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: november Aktiengesellschaft
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Dirk Zurek
CEO
Tel.: +49 (0) 221 82200 520 10
E-Mail: ir@november.de

Branche: Biotechnology
ISIN: DE000A0Z24E9
WKN: A0Z24E
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade